News | October 26, 2021
ANG Life Sciences India H1FY22 consolidated PAT zooms to Rs. 33.77 crore
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
Subscribe To Our Newsletter & Stay Updated
